Dermatological Evaluation of Topic Compatibility - Dermacyd Breeze

Sanofi52 enrolled

Overview

The purpose of this study is to demonstrate the absence of irritation potential (primary dermal irritability and cumulated dermal irritability) and allergy (sensibilization) of the product Dermacyd Pocket BR.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Lactic acid (Dermacid)DRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Phototype Skin I,II, III e IV * Integral skin test in the region Exclusion Criteria: * Use of Antiinflammatory and/or immunosuppression drugs * Personnel history of atopy * History of sensitivity or irritation for topic products * Active cutaneous disease * Use of new drugs or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-aventis administrative office

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

The absence of primary and accumulated dermal irritability and dermal sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.

Time frame: six weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.